For example, ABC-DLBCL tumors driven by specific activating mutations in BCL10 are not sensitive to inhibitors of Bruton’s tyrosine kinase (BTK) — an expected finding since BTK operates upstream of the CBM complex — but do show enhanced sensitivity to MALT1 protease inhibition (52). The gene discussed is BCL10; the disease is diffuse large B-cell lymphoma.